Evidence map›Paper›PMID 29907092›Full record

ArticleBMC medical genetics2018

Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report.

Kristen Westenfield, Kyriakie Sarafoglou, Laura C Speltz, Elizabeth I Pierpont, Joan Steyermark, David Nascene, Matthew Bower, Mary Ella Pierpont

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC medical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Neuromuscular Defects in aBiomolecules · 2025
    Article
  3. Review
  4. Biomedicines · 2023
    Article
  5. SLC35A2-CDG: Novel variant and review.Molecular genetics and metabolism reports · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Kristen WestenfieldDepartment of Pediatrics, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA.
Kyriakie SarafoglouDivisions of Endocrinology, Genetics & Metabolism, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA.
Laura C SpeltzDepartment of Neurology, Gillette Children's Hospital, 200 University Avenue East, St. Paul, MN, 55101, USA.
Elizabeth I PierpontDivision of Clinical Behavioral Neuroscience, Department of Pediatrics, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455-0392, USA.
Joan SteyermarkUniversity of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA.
David NasceneDepartment of Radiology, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN, 55455, USA.
Matthew BowerMolecular Diagnostics Laboratory, University of Minnesota Medical Center, 420 Delaware St SE, Minneapolis, MN, 55455, USA.
Mary Ella PierpontDivision of Genetics & Metabolism, Department of Pediatrics and Ophthalmology, 2450 Riverside Avenue, Minneapolis, MN, 55454, USA. pierp001@umn.edu.ORCID 0000-0002-9943-5236
University of Minnesota · USGillette Children's Specialty Healthcare · USPediatrics and Genetics · USUniversity of Minnesota Children's Hospital · USUniversity of Minnesota Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCongenital disorders of glycosylation are rare conditions caused by genetic defects in glycan synthesis, processing or transport. Most congenital disorders of glycosylation involve defects in the formation or transfer of the lipid-linked oligosaccharide precursor of N-linked glycans. SLC35A2-CDG (previously CDG-IIm) is caused by hemizygous or heterozygous mutations in the X-linked gene SLC35A2 that encodes a UDP-galactose transporter. To date there have only been 10 reported patients with SLC35A2 mutations. Importantly, the patient presented here was not identified in infancy by transferrin isoform analysis, the most common testing to identify patients with a congenital disorder of glycosylation. CASE PRESENTATION: A 27 month old girl with developmental delay, central hypotonia, cerebral atrophy, and failure to thrive with growth retardation was identified by whole exome sequencing to have a mosaic missense variant in SLC35A2 (c.991G > A). This particular variant has been previously reported in a male as a mutation. Comparison of all clinical findings and new information on growth pattern, growth hormone testing and neurodevelopmental evaluation are detailed on the patient presented.

conclusionThis patient report increases the clinical and scientific knowledge of SLC35A2-CDG, a rare condition. New information on reduced growth, growth hormone sufficiency, lack of seizures, and neurodevelopmental status are presented. This new information will be helpful to clinicians caring for individuals with SLC35A2-CDG. This report also alerts clinicians that transferrin isoform measurements do not identify all patients with congenital disorders of glycosylation.

Indexed as

Mutation, MissenseChild, PreschoolCongenital Disorders of GlycosylationFemaleHumansMonosaccharide Transport ProteinsMosaicismPrognosisUDP-Galactose TranslocatorsMonosaccharide Transport ProteinsUDP-Galactose TranslocatorsCongenital disorder of glycosylationGrowth failureSLC35A2 mutationTransferrin isoformsWhole exome sequencing

Identifiers

PMID29907092
PMCPMC6003163
OpenAlexW2808348050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.